SCHEMBL181041

SCHEMBL181041

N#CCc1ccccc1[N+](=O)[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 1.00
HPGD P15428 1/20 1.00
TSHR P16473 1/20 0.58
HTT P42858 1/20 0.49
POLB P06746 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ACHE P22303 1/20 0.43
RECQL P46063 1/20 0.43
MAPT P10636 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28410272 0.90 ALDH1A1 (0.81) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL7291481 0.84 ALDH1A1 (0.72) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL10572196 0.83 ALDH1A1 (0.71) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL8334178 0.83 ALDH1A1 (0.71) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL313581 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRHTTTDP1
SCHEMBL7734149 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL6130889 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL10959778 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL10867768 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRHTTPOLB
SCHEMBL3842149 0.82 ALDH1A1 (0.70) ALDH1A1HPGDTSHRPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121076114-B Lithium iron manganese phosphate/carbon fiber composite positive electrode material and preparation method thereof 湖南裕能新能源电池材料股份有限公司 2026-02-27 CN claimed
CN-110407788-A Fluorine-containing skeleton and its synthetic method UNIV CENTRAL SOUTH 2019-11-05 CN claimed
CN-103483339-B Simple synthesis method of 9H-pyridino-[2, 3-b] indole HUAIYIN TEACHER COLLEGE 2015-03-04 CN claimed
CN-103483339-A Simple synthesis method of 9H-pyridino-[2, 3-b] indole HUAIYIN TEACHER COLLEGE 2014-01-01 CN claimed
EP-1437749-B1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-07-17 EP claimed
US-7732534-B2 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2010-06-08 US claimed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US claimed
US-20080051519-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2008-02-28 US claimed
US-20080051552-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION 2008-02-28 US claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US claimed
CN-1228307-C O-nitrophenylacetic acid and catalysis synthesis of phase transfer UNIV TAIYUAN TECHNOLOGY (CN) 2005-11-23 CN claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US claimed
US-20040199002-A1 Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor INDUSTRY CO., LTD. (JP) 2004-10-07 US claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP claimed
EP-1431278-A1 PROCESS FOR PRODUCING (2-NITROPHENYL)ACETONITRILE DERIVATIVE AND INTERMEDIATE THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2004-06-23 EP claimed
CN-1462738-A O-nitrophenylacetic acid and catalysis synthesis of phase transfer TAIYUAN TECHNICAL UNIV (CN) 2003-12-24 CN claimed
EP-0190087-B1 FORGE-PROOF SECURITY PAPER, PROCESS FOR MAKING A PAPER FORGE-PROOF AND AQUEOUS OR ORGANIC COMPOSITION ESPECIALLY USEFUL IN MAKING A PAPER FORGE-PROOF AUSSEDAT-REY (FR) 1988-04-06 EP claimed
EP-0190087-A1 Forge-proof security paper, process for making a paper forge-proof and aqueous or organic composition especially useful in making a paper forge-proof AUSSEDAT-REY (FR) 1986-08-06 EP claimed
US-4499026-A Nucleophilic substitution process ETHYL CORPORATION (US) 1985-02-12 US claimed
JP-55062061-A None JP disclosed
JP-54126726-A None JP disclosed
US-20260131016-A1 NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC (US) 2026-05-14 US disclosed
CN-121076114-B Lithium iron manganese phosphate/carbon fiber composite positive electrode material and preparation method thereof 湖南裕能新能源电池材料股份有限公司 2026-02-27 CN disclosed
EP-3845515-B1 PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY KANEKA CORP (JP) 2025-11-12 EP disclosed
EP-4131548-B1 NON-AQUEOUS ELECTROLYTE FOR BATTERY, PRECURSOR FOR LITHIUM SECONDARY BATTERY, METHOD FOR MANUFACTURING LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY, PHOSPHAZENE COMPOUND, AND ADDITIVE FOR BATTERY MITSUI CHEMICALS INC (JP) 2025-08-27 EP disclosed
EP-4426714-A1 NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF Adcentrx Therapeutics Inc. (US) 2024-09-11 EP disclosed
CN-118541378-A Novel auristatin analogues and immunoconjugates thereof 艾德森特克斯治疗股份有限公司 2024-08-23 CN disclosed
US-11773043-B2 Systems and methods for producing coenzyme Q10 Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (CN) 2023-10-03 US disclosed
CN-114805796-B Two-dimensional strong fluorescence polyaniline material with metal ion detection performance and preparation method thereof 武汉大学 2023-08-22 CN disclosed
CN-110944970-B For the production of coenzyme Q 10 Systems and methods of (1) 内蒙古金达威药业有限公司 2023-08-01 CN disclosed
WO-2023081230-A1 NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC. (US) 2023-05-11 WO disclosed
US-20230110251-A1 NON-AQUEOUS ELECTROLYTE FOR BATTERY, PRECURSOR FOR LITHIUM SECONDARY BATTERY, METHOD FOR MANUFACTURING LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY, PHOSPHAZENE COMPOUND, AND ADDITIVE FOR BATTERY MITSUI CHEMICALS, INC. (JP) 2023-04-13 US disclosed
CN-111646908-B Method for preparing aromatic amine compound 宜昌尚诺德生物医药科技有限公司 2023-03-10 CN disclosed
EP-4131548-A1 NON-AQUEOUS ELECTROLYTE FOR BATTERY, PRECURSOR FOR LITHIUM SECONDARY BATTERY, METHOD FOR MANUFACTURING LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY, PHOSPHAZENE COMPOUND, AND ADDITIVE FOR BATTERY Mitsui Chemicals, Inc. (JP) 2023-02-08 EP disclosed
CN-111732493-B Synthesis process of arylamine compound 宜昌尚诺德生物医药科技有限公司 2023-01-24 CN disclosed
US-11498893-B2 Production method for crystal of reduced coenzyme Q10 having excellent stability KANEKA CORPORATION (JP) 2022-11-15 US disclosed
CN-115315840-A Nonaqueous electrolyte for battery, lithium secondary battery precursor, method for producing lithium secondary battery, phosphazene compound, and battery additive 三井化学株式会社 2022-11-08 CN disclosed
WO-2022204150-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. (US) 2022-09-29 WO disclosed
US-11453633-B2 Production method for crystal of reduced coenzyme Q10 having excellent stability KANEKA CORPORATION (JP) 2022-09-27 US disclosed
CN-114931967-A Preparation method and application of catalyst for preparing arylamine by selective hydrogenation of aromatic nitro compound 浙江师范大学 2022-08-23 CN disclosed
US-20210355059-A1 PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY KANEKA CORPORATION (JP) 2021-11-18 US disclosed
US-20210317057-A1 PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY KANEKA CORPORATION (JP) 2021-10-14 US disclosed
EP-3845515-A1 PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY Kaneka Corporation (JP) 2021-07-07 EP disclosed
CN-112839921-A Method for producing highly stable reduced coenzyme Q10 crystal 株式会社钟化 2021-05-25 CN disclosed
US-20210032666-A1 METHOD FOR PRODUCING COENZYME Q10 KANEKA CORPORATION (JP) 2021-02-04 US disclosed
CN-111995577-A Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof 上海代为化学科技有限公司 2020-11-27 CN disclosed
US-10837043-B2 Method for producing coenzyme Q10 KANEKA CORPORATION (JP) 2020-11-17 US disclosed
CN-111732493-A Synthesis process of arylamine compound 宜昌尚诺德生物医药科技有限公司 2020-10-02 CN disclosed
CN-111646908-A Method for preparing aromatic amine compound 宜昌尚诺德生物医药科技有限公司 2020-09-11 CN disclosed
US-20200208189-A9 METHOD FOR PRODUCING COENZYME Q10 KANEKA CORPORATION (JP) 2020-07-02 US disclosed
CN-106800493-B Method for reducing aromatic nitro group into aromatic amine 宜昌尚诺德生物医药科技有限公司 2020-06-30 CN disclosed
CN-110981825-A 2-nitrobenzophenones and process for their preparation 安徽省化工研究院 2020-04-10 CN disclosed
WO-2020067275-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY 株式会社カネカ 2020-04-02 WO disclosed
CN-110944970-A For producing coenzyme Q10System and method 内蒙古金达威药业有限公司 2020-03-31 CN disclosed
US-20200087235-A1 SYSTEMS AND METHODS FOR PRODUCING COENZYME Q10 Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (CN) 2020-03-19 US disclosed
WO-2020045571-A1 PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY 株式会社カネカ 2020-03-05 WO disclosed
WO-2020029017-A1 SYSTEMS AND METHODS FOR PRODUCING COENZYME Q10 Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (CN) 2020-02-13 WO disclosed
US-10471139-B2 Toll-like receptor agonists THE UNIVERSITY OF KANSAS (US) 2019-11-12 US disclosed
CN-110407788-A Fluorine-containing skeleton and its synthetic method UNIV CENTRAL SOUTH 2019-11-05 CN disclosed
WO-2019189290-A1 COENZYME Q10 PRODUCTION METHOD 株式会社カネカ 2019-10-03 WO disclosed
EP-3480317-A1 METHOD FOR PRODUCING COENZYME Q10 Kaneka Corporation (JP) 2019-05-08 EP disclosed
US-20190127773-A1 METHOD FOR PRODUCING COENZYME Q10 KANEKA CORPORATION (JP) 2019-05-02 US disclosed
US-10239811-B2 Process for producing reduced coenzyme Q10 KANEKA CORPORATION (JP) 2019-03-26 US disclosed
CN-108997129-A A kind of synthetic method of o-nitrophenyl acetic acid 江苏师范大学 2018-12-14 CN disclosed
CN-108752215-A A kind of synthetic method of o-nitrophenyl acetic acid 杨程飞扬 2018-11-06 CN disclosed
EP-2489652-B1 METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME KANEKA CORP (JP) 2018-07-25 EP disclosed
US-10021877-B2 Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-07-17 US disclosed
EP-2597156-B1 METHOD FOR MANUFACTURING A FAT-SOLUBLE BIOACTIVE SUBSTANCE KANEKA CORP (JP) 2018-06-27 EP disclosed
EP-1583729-B1 METHOD OF PURIFYING REDUCED COENZYME Q KANEKA CORP (JP) 2018-06-06 EP disclosed
US-20180134644-A1 PROCESS FOR PRODUCING REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2018-05-17 US disclosed
EP-3321248-A2 METHOD OF PRODUCING REDUCED COENZYME Q10 USING SOLVENT WITH HIGH OXIDATION-PROTECTIVE EFFECT Kaneka Corporation (JP) 2018-05-16 EP disclosed
EP-3003036-B1 SUBSTITUTED 5-HYDROXY-2,3-DIPHENYLPENTANONITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS BAYER CROPSCIENCE AG (DE) 2018-04-11 EP disclosed
US-9926580-B2 Process for producing coenzyme Q10 KANEKA CORPORATION (JP) 2018-03-27 US disclosed
EP-2725004-B1 REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY KANEKA CORP (JP) 2018-02-28 EP disclosed
EP-3279180-A1 METHOD FOR STABILIZATION OF REDUCED COENZYME Q10 Kaneka Corporation (JP) 2018-02-07 EP disclosed
EP-1415970-B1 METHOD OF PRODUCING REDUCED COENZYME Q10 CRYSTALS WITH EXCELLENT HANDLING PROPERTIES KANEKA CORP (JP) 2017-12-20 EP disclosed
EP-2489653-B1 METHOD FOR PRODUCING REDUCED COENZYME Q10 AND COMPOSITION COMPRISING SAME KANEKA CORP (JP) 2017-11-29 EP disclosed
EP-2289866-B1 METHOD OF PRODUCING REDUCED COENZYME Q10 AS OILY PRODUCT KANEKA CORP (JP) 2017-08-30 EP disclosed
EP-3197435-A1 SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL) METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO Millendo Therapeutics, Inc. (US) 2017-08-02 EP disclosed
EP-2017251-B1 METHOD FOR STABILIZATION OF REDUCED COENZYME Q10 KANEKA CORP (JP) 2017-07-19 EP disclosed
EP-1415971-B1 METHOD OF PRODUCING REDUCED COENZYME Q10 AS OILY PRODUCT KANEKA CORP (JP) 2017-03-22 EP disclosed
US-9556098-B2 Reduced coenzyme Q10 crystal having excellent stability KANEKA CORPORATION (JP) 2017-01-31 US disclosed
US-9532957-B2 Method of stabilizing reduced coenzyme Q10 KANEKA CORPORATION (JP) 2017-01-03 US disclosed
US-9518004-B2 Reduced coenzyme Q10 derivative and method for production thereof KANEKA CORPORATION (JP) 2016-12-13 US disclosed
US-20160304915-A1 PROCESS FOR PRODUCING COENZYME Q10 KANEKA CORP (JP) 2016-10-20 US disclosed
US-20160289152-A1 REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY KANEKA CORPORATION (JP) 2016-10-06 US disclosed
US-9440901-B2 Method for producing reduced coenzyme Q10 KANEKA CORPORATION (JP) 2016-09-13 US disclosed
CN-105820165-A Alpha-carboline compounds, preparation method thereof and purpose thereof 中国科学院上海药物研究所 2016-08-03 CN disclosed
WO-2016110237-A1 Α-CARBOLINE COMPOUND , PREPARATION METHOD THEREFOR AND USES THEREOF 中国科学院上海药物研究所 2016-07-14 WO disclosed
US-9388109-B2 Reduced coenzyme Q10 crystal having excellent stability KANEKA CORPORATION (JP) 2016-07-12 US disclosed
US-20160166681-A1 TOLL-LIKE RECEPTOR AGONISTS THE UNIVERSITY OF KANSAS 2016-06-16 US disclosed
US-20160166681-A1 TOLL-LIKE RECEPTOR AGONISTS THE UNIVERSITY OF KANSAS 2016-06-16 US disclosed
US-20160166681-A1 TOLL-LIKE RECEPTOR AGONISTS THE UNIVERSITY OF KANSAS 2016-06-16 US disclosed
US-20160113277-A1 Substituted 5-Hydroxy-2,3-Diphenylpentanonitrile Derivatives, Processes For Their Preparation And Their Use As Herbicides And/Or Plant Growth Regulators BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-04-28 US disclosed
US-9315839-B2 Processes for producing coenzyme Q10 KANEKA CORPORATION (JP) 2016-04-19 US disclosed
EP-3003036-A1 SUBSTITUTED 5-HYDROXY-2,3-DIPHENYLPENTANONITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS Bayer CropScience Aktiengesellschaft (DE) 2016-04-13 EP disclosed
WO-2016049518-A1 SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL) METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO MILLENDO THERAPEUTICS, INC. (US) 2016-03-31 WO disclosed
CN-103025881-B Process for preparing fat-soluble physiologically active substance KANEKA CORP. (JP) 2016-03-30 CN disclosed
EP-2947082-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2015-11-25 EP disclosed
WO-2015162536-A1 NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) 2015-10-29 WO disclosed
US-20150307440-A1 REDUCED COENZYME Q10 DERIVATIVE AND METHOD FOR PRODUCTION THEREOF KANEKA CORPORATION (JP) 2015-10-29 US disclosed
US-20150284311-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2015-10-08 US disclosed
US-9139587-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2015-09-22 US disclosed
EP-2676958-B1 N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-01 EP disclosed
CN-104744302-A Preparation method of 2-(4-aminophenyl)-2-methyl propionitrile compound SHANGHAI PHARMVALLEY CORP 2015-07-01 CN disclosed
US-9040747-B2 Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same KANEKA CORPORATION (JP) 2015-05-26 US disclosed
US-9012230-B2 Fluorescent nanoprobe for detecting hydrogen peroxide and fabrication method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-04-21 US disclosed
CN-102656133-B Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same KANEKA CORP 2015-04-15 CN disclosed
US-9006493-B2 Method for manufacturing a fat-soluble bioactive substance KANEKA CORPORATION (JP) 2015-04-14 US disclosed
CN-103483339-B Simple synthesis method of 9H-pyridino-[2, 3-b] indole HUAIYIN TEACHER COLLEGE 2015-03-04 CN disclosed
WO-2015023958-A1 TOLL-LIKE RECEPTOR AGONISTS THE UNIVERSITY OF KANSAS (US) 2015-02-19 WO disclosed
WO-2015023958-A1 TOLL-LIKE RECEPTOR AGONISTS THE UNIVERSITY OF KANSAS (US) 2015-02-19 WO disclosed
WO-2014195253-A1 SUBSTITUTED 5-HYDROXY-2,3-DIPHENYLPENTANONITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS BAYER CROPSCIENCE AG (DE) 2014-12-11 WO disclosed
CN-102695708-B N1-pyrazolospiroketone acetyl-coA carboxylase inhibitors PFIZER INC. (US) 2014-10-15 CN disclosed
US-8853464-B2 Method of producing reduced coenzyme Q10 crystals with excellent handling properties KANEKA CORPORATION (JP) 2014-10-07 US disclosed
CN-102381948-B Method of stabilizing reduced coenzyme Q10 KANEKA CORP. (JP) 2014-10-01 CN disclosed
US-20140288111-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2014-09-25 US disclosed
CN-101842340-B Method for production of reduced coenzyme Q10 using water-containing organic solvent KANEKA CORP 2014-08-13 CN disclosed
US-8802690-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2014-08-12 US disclosed
US-20140212402-A1 METHOD OF STABILIZING REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2014-07-31 US disclosed
CN-102056897-B Sulfonamide compound and application thereof ASAHI KASEI PHARMA CORP 2014-05-07 CN disclosed
US-20140120073-A1 REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY KANEKA CORPORATION (JP) 2014-05-01 US disclosed
EP-2725004-A1 REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY Kaneka Corporation (JP) 2014-04-30 EP disclosed
US-8703155-B2 Method of stabilizing reduced coenzyme q10 KANEKA CORPORATION (JP) 2014-04-22 US disclosed
CN-103635452-A Reduced coenzyme Q10 crystal having excellent stability KANEKA CORP 2014-03-12 CN disclosed
CN-102675151-B Preparation method of nitrophenylacetonitrile compound BEIJING YINGTAI JIAHE BIOLOG TECHNOLOGY CO LTD 2014-02-19 CN disclosed
CN-102675151-B Preparation method of nitrophenylacetonitrile compound BEIJING YINGTAI JIAHE BIOLOG TECHNOLOGY CO LTD 2014-02-19 CN disclosed
CN-103483339-A Simple synthesis method of 9H-pyridino-[2, 3-b] indole HUAIYIN TEACHER COLLEGE 2014-01-01 CN disclosed
EP-2186789-B1 METHOD OF PRODUCING REDUCED COENZYME Q10 AND METHOD OF STABILIZING THE SAME KANEKA CORP (JP) 2013-12-25 EP disclosed
EP-2676958-A1 N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Inc. (US) 2013-12-25 EP disclosed
EP-1452174-B1 STABILIZED COMPOSITION COMPRISING REDUCED COENZYME Q10 KANEKA CORP (JP) 2013-12-18 EP disclosed
EP-2499139-B1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER (US) 2013-12-11 EP disclosed
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. 2013-11-07 US disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
EP-2380568-B1 Method of producing and crystallizing reduced coenzyme Q10 KANEKA CORP (JP) 2013-09-11 EP disclosed
US-20130225868-A1 METHOD FOR MANUFACTURING A FAT-SOLUBLE BIOACTIVE SUBSTANCE KANEKA CORPORATION (JP) 2013-08-29 US disclosed
US-8507681-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2013-08-13 US disclosed
EP-1437749-B1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-07-17 EP disclosed
US-20130142767-A1 COMPOSITION CONTAINING REDUCED COENZYME Q10, AND MANUFACTURING AND STABILISING METHODS THEREFOR KENEKA CORPORATION (JP) 2013-06-06 US disclosed
EP-2597156-A1 METHOD FOR MANUFACTURING A FAT-SOLUBLE BIOACTIVE SUBSTANCE Kaneka Corporation (JP) 2013-05-29 EP disclosed
US-8445734-B2 Photolabile protective groups for improved processes to prepare oligonucleotide arrays NIGU CHEMIE GMBH (DE) 2013-05-21 US disclosed
US-8445734-B2 Photolabile protective groups for improved processes to prepare oligonucleotide arrays NIGU CHEMIE GMBH (DE) 2013-05-21 US disclosed
EP-1460660-B1 ELECTROLYTIC CAPACITOR AND ELECTROLYTIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-04-10 EP disclosed
CN-103025881-A Process for preparing fat-soluble physiologically active substance KANEKA CORP 2013-04-03 CN disclosed
US-8373160-B2 Electrophotographic photoreceptor, process cartridge image forming apparatus, and cured film FUJI XEROX CO., LTD. (JP) 2013-02-12 US disclosed
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC. (US) 2013-01-31 US disclosed
CN-101432256-B Stable reduced coenzyme Q10Method (2) KANEKA CORP 2012-11-28 CN disclosed
US-20120276651-A1 FLUORESCENT NANOPROBE FOR DETECTING HYDROGEN PEROXIDE AND FABRICATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-01 US disclosed
US-8288405-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-10-16 US disclosed
EP-2499140-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
EP-2499139-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
CN-102675151-A Preparation method of nitrophenylacetonitrile compound BEIJING YINGTAI JIAHE BIOLOG TECHNOLOGY CO LTD 2012-09-19 CN disclosed
CN-102675151-A Preparation method of nitrophenylacetonitrile compound BEIJING YINGTAI JIAHE BIOLOG TECHNOLOGY CO LTD 2012-09-19 CN disclosed
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-09-06 US disclosed
EP-2292592-B1 SULFONAMIDE COMPOUND AND APPLICATION THEREOF ASAHI KASEI PHARMA CORP (JP) 2012-09-05 EP disclosed
CN-102656133-A Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same KANEKA CORP 2012-09-05 CN disclosed
CN-102656134-A Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same KANEKA CORP 2012-09-05 CN disclosed
EP-2489652-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME Kaneka Corporation (JP) 2012-08-22 EP disclosed
EP-2489653-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME Kaneka Corporation (JP) 2012-08-22 EP disclosed
US-20120207731-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME KANEKA CORPORATION (JP) 2012-08-16 US disclosed
US-20120201802-A1 METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME KENEKA CORPORATION (JP) 2012-08-09 US disclosed
CN-101318889-B Reduced coenzyme Q10Method for stabilizing KANEGAFUCHI CHEMICAL IND 2012-05-30 CN disclosed
CN-102381948-A Method of stabilizing reduced coenzyme Q10 KANEKA CORP 2012-03-21 CN disclosed
EP-2402303-A2 A reduced coenzyme Q10 crystal Kaneka Corporation (JP) 2012-01-04 EP disclosed
US-8063254-B2 Method for production of reduced coenzyme Q10 using water-containing organic solvent KANEKA CORPORATION (JP) 2011-11-22 US disclosed
US-20110263906-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 CRYSTALS WITH EXCELLENT HANDLING PROPERTIES KANEKA CORPORATION (JP) 2011-10-27 US disclosed
EP-2380568-A1 Method of producing and crystallizing reduced coenzyme Q10 KANEKA CORPORATION (JP) 2011-10-26 EP disclosed
WO-2011130395-A1 INHIBITORS OF FLIP TO TREAT CANCER UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-20 WO disclosed
EP-2377524-A1 Method of stabilizing reduced coenzyme Q10 KANEKA CORPORATION (JP) 2011-10-19 EP disclosed
US-8039514-B2 Sulfonamide compounds and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2011-10-18 US disclosed
US-20110215303-A1 ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE IMAGE FORMING APPARATUS, AND CURED FILM FUJI XEROX CO., LTD. (JP) 2011-09-08 US disclosed
US-8003828-B2 Method of producing reduced coenzyme Q10 crystals with excellent handling properties KANEKA CORPORATION (JP) 2011-08-23 US disclosed
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20110136191-A1 Processes for producing coenzyme Q10 KANEKA CORPORATION (JP) 2011-06-09 US disclosed
US-20110123505-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 AND METHOD OF STABILIZING THE SAME KANEKA CORPORATION (JP) 2011-05-26 US disclosed
WO-2011058474-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
WO-2011058473-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC 2011-05-12 US disclosed
CN-102056897-A Sulfonamide compound and application thereof ASAHI KASEI PHARMA CORP 2011-05-11 CN disclosed
US-7910340-B2 Extracting reduced/oxidized forms via microbial cells; solvent extraction; industrial scale KANEKA CORPORATION (JP) 2011-03-22 US disclosed
EP-2292592-A1 SULFONAMIDE COMPOUND AND APPLICATION THEREOF Asahi Kasei Pharma Corporation (JP) 2011-03-09 EP disclosed
EP-2289866-A2 Method of producing reduced coenzyme Q10 as oily product Kaneka Corporation (JP) 2011-03-02 EP disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100292458-A1 NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS NIGU CHEMIE GMBH (DE) 2010-11-18 US disclosed
US-20100292458-A1 NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS NIGU CHEMIE GMBH (DE) 2010-11-18 US disclosed
US-7829080-B2 Stabilization method of reduced coenzyme Q10 KANEKA CORPORATION (JP) 2010-11-09 US disclosed
EP-1408024-B1 METHOD OF CRYSTALLIZING REDUCED COENZYME Q sb 10 /sb FROM AQUEOUS SOLUTION KANEKA CORP (JP) 2010-10-20 EP disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
CN-101842340-A Method for production of reduced coenzyme Q10 using water-containing organic solvent KANEKA CORP 2010-09-22 CN disclosed
US-20100234643-A1 METHOD FOR PRODUCTION OF REDUCED COENZYME Q10 USING WATER-CONTAINING ORGANIC SOLVENT KANEKA CORPORATION (JP) 2010-09-16 US disclosed
EP-2228360-A1 Method of producing reduced coenzyme Q10 using solvent with high oxidation-protective effect KANEKA CORPORATION (JP) 2010-09-15 EP disclosed
EP-1981504-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES REMYND NV (BE) 2010-07-21 EP disclosed
CN-101219967-B Process for producing 2-nitryl substituted benzene ethane nitrile compounds SHANGHAI INST TECHNOLOGY 2010-07-14 CN disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
US-7732534-B2 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2010-06-08 US disclosed
EP-2186789-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 AND METHOD OF STABILIZING THE SAME Kaneka Corporation (JP) 2010-05-19 EP disclosed
WO-2010028174-A1 NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed
US-7660101-B2 Electrolytic capacitor and electrolyte solution for use in an electrolytic capacitor RUBYCON CORPORATION (JP) 2010-02-09 US disclosed
US-20100022601-A1 SULFONAMIDE COMPOUNDS AND THE USE ASAHI KASEI PHARMA CORPORATION (JP) 2010-01-28 US disclosed
EP-1415973-B1 METHOD OF STABILIZING REDUCED COENZYME Q10 AND METHOD OF ACIDIC CRYSTALLIZATION KANEKA CORP (JP) 2010-01-13 EP disclosed
US-7592460-B2 Colorant compositions XEROX CORPORATION (US) 2009-09-22 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 EP disclosed
CN-100523205-C Processes for producing coenzyme Q10 KANEGAFUCHI CHEMICAL IND (JP) 2009-08-05 CN disclosed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US disclosed
CN-101432256-A Stable reduced coenzyme Q10Method (2) KANEGAFUCHI CHEMICAL IND (JP) 2009-05-13 CN disclosed
US-7524993-B2 Method of producing reduced coenzyme Q10 as oily product KANEKA CORPORATION (JP) 2009-04-28 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed
EP-2025662-A1 METHOD FOR PURIFICATION OF REDUCED COENZYME Q10 Kaneka Corporation (JP) 2009-02-18 EP disclosed
EP-2017251-A1 METHOD FOR STABILIZATION OF REDUCED COENZYME Q10 Kaneka Corporation (JP) 2009-01-21 EP disclosed
US-7470815-B1 Selective neuronal nitric oxide synthase inhibitors NORTHWESTERN UNIVERSITY (US) 2008-12-30 US disclosed
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 US disclosed
CN-101318889-A Method of stabilizing reduced coenzyme Q10 KANEGAFUCHI CHEMICAL IND (JP) 2008-12-10 CN disclosed
CN-101296911-A Arylurea derivatives as modulators of chemokine receptor activity NOVARTIS AG (CH) 2008-10-29 CN disclosed
EP-1981504-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV Remynd (BE) 2008-10-22 EP disclosed
US-20080176830-A1 Compounds, Compositions, and Methods ADAMS NICHOLAS D 2008-07-24 US disclosed
US-20080171373-A1 Processes for producing coenzyme Q10 KANEKA CORPORATION 2008-07-17 US disclosed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 EP disclosed
CN-101219967-A Process for producing 2-nitryl substituted benzene ethane nitrile compounds SHANGHAI INST TECHNOLOGY (CN) 2008-07-16 CN disclosed
EP-1471115-B1 Methine dyes with a polyoxyalkylene moiety and inks containing them XEROX CORP (US) 2008-07-09 EP disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed
CN-101189237-A Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT CO (US) 2008-05-28 CN disclosed
US-20080099112-A1 Reduced sensitivity melt-pourable Tritonal replacements ALLIANT TECHSYSTEMS INC. 2008-05-01 US disclosed
EP-1466983-B1 PROCESSES FOR PRODUCING COENZYME Q10 KANEKA CORP (JP) 2008-03-05 EP disclosed
US-20080051519-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2008-02-28 US disclosed
US-20080051552-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION 2008-02-28 US disclosed
EP-1874753-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 EP disclosed
EP-1869041-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2007-12-26 EP disclosed
US-20070258967-A1 PURIFICATION METHOD OF REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2007-11-08 US disclosed
US-20070258966-A1 STABILIZATION METHOD OF REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2007-11-08 US disclosed
CN-101061116-A Sulfonamide compounds JANSSEN PHARMACEUTICA NV (BE) 2007-10-24 CN disclosed
CN-100344595-C Purification of reduced coenzyme Q10Method (2) KANEGAFUCHI CHEMICAL IND (JP) 2007-10-24 CN disclosed
US-7279117-B2 Electrolytic capacitor and electrolyte solution for use in an electrolytic capacitor RUBYCON CORPORATION (JP) 2007-10-09 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed
WO-2007090617-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2007-08-16 WO disclosed
US-20070171595-A1 Electrolytic capacitor and electrolyte solution for use in an electrolytic capacitor RUBYCON CORPORATION (JP) 2007-07-26 US disclosed
US-20070161825-A1 Method of producing reduced coenzyme Q10 as oily product KANEKA CORPORATION 2007-07-12 US disclosed
EP-1415972-B1 METHOD OF PRODUCING REDUCED COENZYME Q10 KANEKA CORP (JP) 2007-05-23 EP disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO disclosed
US-7208639-B2 Method of producing reduced coenzyme Q10 as oily product KANEKA CORPORATION (JP) 2007-04-24 US disclosed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US disclosed
EP-1401813-B1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY HOFFMANN LA ROCHE (CH) 2007-02-07 EP disclosed
US-7169590-B2 Method of stabilizing reduced coenzyme Q10 and method of acidic crystallization KANEKA CORPORATION (JP) 2007-01-30 US disclosed
US-7145044-B2 Method of producing reduced coenzyme Q10 using solvent with high oxidation-protective effect KANEKA CORPORATION (JP) 2006-12-05 US disclosed
US-20060246565-A1 Method of purifying reduced coenzyme q KANEKA CORPORATION (JP) 2006-11-02 US disclosed
WO-2006113432-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 WO disclosed
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2006-10-19 US disclosed
WO-2006103559-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2006-10-05 WO disclosed
US-7105709-B2 Method of producing reduced coenzyme q10 KANEKA CORPORATION (JP) 2006-09-12 US disclosed
EP-1583729-A4 METHOD OF PURIFYING REDUCED COENZYME Q KANEKA CORP (JP) 2006-07-05 EP disclosed
US-7067024-B2 Reduced sensitivity, melt-pourable TNT replacements ALLIANT TECHSYSTEMS INC. (US) 2006-06-27 US disclosed
CN-1257892-C New indole derivatives with 5-HT6 receptor affinity HOFFMANN LA ROCHE (CH) 2006-05-31 CN disclosed
CN-1254462-C Reduced coenzyme Q10Method for stabilization of (3) and method for acid crystallization KANEGAFUCHI CHEMICAL IND (JP) 2006-05-03 CN disclosed
US-7034185-B2 Colorant precursor compositions XEROX CORPORATION (US) 2006-04-25 US disclosed
CN-1723181-A Method of purifying reduced coenzyme Q KANEGAFUCHI CHEMICAL IND (JP) 2006-01-18 CN disclosed
US-20050277630-A1 Antibacterial agents CHUPAK LOUIS S 2005-12-15 US disclosed
CN-1228307-C O-nitrophenylacetic acid and catalysis synthesis of phase transfer UNIV TAIYUAN TECHNOLOGY (CN) 2005-11-23 CN disclosed
EP-1594495-A1 OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2005-11-16 EP disclosed
US-6964714-B2 Reduced sensitivity, melt-pourable tritonal replacements ALLIANT TECHSYSTEMS INC. (US) 2005-11-15 US disclosed
US-20050250796-A1 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2005-11-10 US disclosed
EP-1367058-B1 Tetrahydropyran derivatives ASTELLAS PHARMA INC (JP) 2005-11-09 EP disclosed
US-20050239780-A1 Tetrahydropyran derivative ASTELLAS PHARMA INC. (JP) 2005-10-27 US disclosed
EP-1583729-A1 METHOD OF PURIFYING REDUCED COENZYME Q KANEKA CORPORATION (JP) 2005-10-12 EP disclosed
CN-1656091-A Tetrahydropyran derivatives YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 CN disclosed
US-20050171118-A1 New indole derivatives with 5-HT6 receptor affinity BEARD COLIN C (US) 2005-08-04 US disclosed
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists KOSOGOF CHRISTI (US) 2005-08-04 US disclosed
US-20050159363-A1 Selective neuronal nitric oxide synthase inhibitors SILVERMAN RICHARD B (US) 2005-07-21 US disclosed
US-20050094352-A1 Electrolytic capacitor and electrolitic solution for driving electrolytic capacitor RUBYCON CORPORATION (JP) 2005-05-05 US disclosed
CN-1608136-A Processes for producing coenzyme Q10 KANEKA CORP (JP) 2005-04-20 CN disclosed
US-20050069996-A1 Extracting reduced/oxidized forms via microbial cells KANEKA CORPORATION (JP) 2005-03-31 US disclosed
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators ABBOTT LABORATORIES 2005-03-31 US disclosed
CN-1578760-A Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor IHARA CHEMICAL IND CO (JP) 2005-02-09 CN disclosed
CN-1572754-A Method for producing organic compound by substituting halogen atoms MITSUI CHEMICALS INC (JP) 2005-02-02 CN disclosed
US-20050008630-A1 Preservation; nutrients; foods; using ascorbic and citric acid; oxidation resistance; by-product inhibition KANEKA CORPORATION (JP) 2005-01-13 US disclosed
US-20040256743-A1 Method for producing organic compound by substituting halogen atoms MITSUI CHEMICALS, INC. (JP) 2004-12-23 US disclosed
US-20040254403-A1 Method of producing reduced coenzyme q10 as oily product KANEKA CORPORATION (JP) 2004-12-16 US disclosed
EP-1486479-A1 Method for producing organic compounds by substituting halogen atoms MITSUI CHEMICALS, INC. (JP) 2004-12-15 EP disclosed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US disclosed
US-20040248902-A1 New indole derivatives with 5-HT6 receptor affinity BEARD COLIN CHARLES (US) 2004-12-09 US disclosed
US-20040236154-A1 Method of producing reduced coenzyme q10 KANEKA CORPORATION (JP) 2004-11-25 US disclosed
US-20040215038-A1 Colorant precursor compositions XEROX CORPORATION 2004-10-28 US disclosed
US-20040214301-A1 Using cooled ethanol and acetone mixtures to generate and isolate coenzyme q10 crystals for use in nutritive foods, drinks, feeds, cosmetics and medicines KANEKA CORPORATION (JP) 2004-10-28 US disclosed
US-20040215040-A1 Method of producing reduced coenzyme q10 using solvent with high oxidation-protective effect KANEKA CORPORATION (JP) 2004-10-28 US disclosed
US-20040215022-A1 Colorant compositions XEROX CORPORATION 2004-10-28 US disclosed
EP-1471115-A1 Methine dyes with a polyoxyalkylene moiety and inks containing them Xerox Corporation (US) 2004-10-27 EP disclosed
EP-1471118-A1 Colorant precursor compounds containing one polyoxyalkylene group Xerox Corporation (US) 2004-10-27 EP disclosed
EP-1466983-A1 PROCESSES FOR PRODUCING COENZYME Q SB 10 /SB KANEKA CORPORATION (JP) 2004-10-13 EP disclosed
US-6803486-B2 PEPTIDOMIMETIC; N-AMINOBUTYL-N'-NITROGUANIDINE DERIVATIVES NORTHWESTERN UNIVERSITY 2004-10-12 US disclosed
US-20040199002-A1 Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor INDUSTRY CO., LTD. (JP) 2004-10-07 US disclosed
US-20040197886-A1 Method of crystallizing reduced coenzyme Q10 from aqueous solution KANEKA CORPORATION (JP) 2004-10-07 US disclosed
US-20040197418-A1 Method of stabilizing reduced coenzyme q10 and method of acidic crystallization KANEKA CORPORATION (JP) 2004-10-07 US disclosed
EP-1460660-A1 ELECTROLYTIC CAPACITOR AND ELECTROLITIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-09-22 EP disclosed
US-6790267-B1 METHINE COLORANT COMPOUNDS FOR PHASE CHANGE INKS XEROX CORPORATION 2004-09-14 US disclosed
CN-1527816-A Novel indole derivatives having 5-HT 6 receptor affinity - 2004-09-08 CN disclosed
US-6787535-B2 CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-09-07 US disclosed
EP-1452174-A1 METHOD OF STABILIZING REDUCED COENZYME Q sb 10 /sb KANEKA CORPORATION (JP) 2004-09-01 EP disclosed
CN-1525951-A Reduced coenzyme Q10Method for stabilization of (3) and method for acid crystallization ��Ԩ��ѧ��ҵ��ʽ���� 2004-09-01 CN disclosed
WO-2004069245-A1 OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-19 WO disclosed
WO-2004063131-A1 METHOD OF PURIFYING REDUCED COENZYME Q KANEKA CORPORATION (JP) 2004-07-29 WO disclosed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP disclosed
EP-1431278-A1 PROCESS FOR PRODUCING (2-NITROPHENYL)ACETONITRILE DERIVATIVE AND INTERMEDIATE THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2004-06-23 EP disclosed
EP-1415971-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 AS OILY PRODUCT KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
EP-1415969-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 USING SOLVENT WITH HIGH OXIDATION-PROTECTIVE EFFECT KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
EP-1415973-A1 METHOD OF STABILIZING REDUCED COENZYME Q10 AND METHOD OF ACIDIC CRYSTALLIZATION KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
EP-1415972-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
EP-1415970-A1 METHOD OF PRODUCING REDUCED COENZYME Q10 CRYSTALS WITH EXCELLENT HANDLING PROPERTIES KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
EP-1408024-A1 METHOD OF CRYSTALLIZING REDUCED COENZYME Q sb 10 /sb FROM AQUEOUS SOLUTION KANEKA CORPORATION (JP) 2004-04-14 EP disclosed
EP-1401813-A1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY F. Hoffman-la Roche AG (CH) 2004-03-31 EP disclosed
EP-1399400-A1 REDUCED SENSITIVITY, MELT-POURABLE TNT REPLACEMENTS ALLIANT TECHSYSTEMS INC. (US) 2004-03-24 EP disclosed
EP-1399399-A1 REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS ALLIANT TECHSYSTEMS INC. (US) 2004-03-24 EP disclosed
CN-1138763-C Di- or tri-fluoromethanesulfonyl anilide derivs., process for preparation of them and herbicides contg. them as active ingredient ��Ԩ��ѧ��ҵ��ʽ���� 2004-02-18 CN disclosed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
CN-1462738-A O-nitrophenylacetic acid and catalysis synthesis of phase transfer TAIYUAN TECHNICAL UNIV (CN) 2003-12-24 CN disclosed
EP-1367058-A1 Tetrahydropyran derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-12-03 EP disclosed
EP-1361218-A1 Trifluoromethanesulfonyl anilide derivatives, process for the preparation of them and herbicides containing them as the active ingredient IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2003-11-12 EP disclosed
EP-1101760-B1 DIFLUOROMETHANESULFONYL ANILIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF THEM AND HERBICIDES CONTAINING THEM AS THE ACTIVE INGREDIENT IHARA CHEMICAL IND CO (JP) 2003-10-15 EP disclosed
US-20030140993-A1 Reduced sensitivity, melt-pourable tritonal replacements NORTHROP GRUMMAN SYSTEMS CORPORATION 2003-07-31 US disclosed
CN-1115329-C Process for preparing p-nitrophenyl acetonitrile by directional nitrification WEI CHANGMEI (CN) 2003-07-23 CN disclosed
US-20030119751-A1 Selective neuronal nitric oxide synthase inhibitors NORTHWESTERN UNIVERSITY 2003-06-26 US disclosed
JP-2003171359-A METHOD FOR PRODUCING 2-NITROPHENYLACETONITRILE DERIVATIVE, AND ITS SYNTHETIC INTERMEDIATE IHARA CHEM IND CO LTD 2003-06-20 JP disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC 2003-04-17 US disclosed
WO-2003002486-A1 REDUCED SENSITIVITY, MELT-POURABLE TNT REPLACEMENTS ALLIANT TECHSYSTEMS INC. (US) 2003-01-09 WO disclosed
WO-2003002485-A1 REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS ALLIANT TECHSYSTEMS INC. (US) 2003-01-09 WO disclosed
US-20030005988-A1 Reduced sensitivity, melt-pourable TNT replacements NORTHROP GRUMMAN SYSTEMS CORPORATION 2003-01-09 US disclosed
WO-2003000198-A2 SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS NORTHWESTERN UNIVERSITY (US) 2003-01-03 WO disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
WO-2002098857-A1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed
US-6458748-B1 COMPOUND WHICH IS EFFECTIVE FOR THE REMOVAL OF A WIDE VARIETY OF WEEDS INCLUDING DIFFICULT-TO-CONTROL WEEDS EMERGING IN PADDY FIELD AND WHICH IS SAFE TO MAMMALS; A PROCESS FOR PRODUCTION THEREOF; A HERBICIDE CONTAINING THE COMPOUND AS AN IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2002-10-01 US disclosed
US-6455522-B1 ANTIINFLAMMATORY AGENTS; AGGRECANASE AND TUMOR NECROSIS FACTOR INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-24 US disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0796852-B1 Process for preparation of 5-substituted tetrazoles TOYO KASEI KOGYO CO LTD (JP) 2001-10-24 EP disclosed
CN-1309646-A Di- or tri-fluoromethanesulfonyl anilide derivs., process for preparation of them and herbicides contg. them as active ingredient IHARA CHEMICAL IND CO (JP) 2001-08-22 CN disclosed
CN-1305988-A Process for preparing p-nitrophenyl acetonitrile by directional nitrification WEI CHANGMEI (CN) 2001-08-01 CN disclosed
EP-1101760-A1 DI- OR TRI-FLUOROMETHANESULFONYL ANILIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF THEM AND HERBICIDES CONTAINING THEM AS THE ACTIVE INGREDIENT IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2001-05-23 EP disclosed
US-6179883-B1 USING 2-IMINO-2,3-DIHYDRO-1H-INDOLE MIXTURE L'OREAL (FR) 2001-01-30 US disclosed
EP-1054877-A1 NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-11-29 EP disclosed
US-6040454-A REACTING 1-(CYANOBIPHENYLMETHYL)IMIDAZOLE DERIVATIVE WITH AN ALKALI OR ALKALINE EARTH METAL AZIDE SALT IN AN AROMATIC HYDROCARBON SOLVENT IN PRESENCE OF AN AMINE SALT TOYO KASEI KOGYO COMPANY LIMITED (JP) 2000-03-21 US disclosed
US-5962492-A ANTIASTHMA AGENTS; ANTIINFLAMMATORY AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 1999-10-05 US disclosed
WO-1999041246-A1 NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-08-19 WO disclosed
US-5919469-A Products derived from 2-imino-2,3-dihydro-1H-indoles, processes for their preparation, their use in cosmetics and cosmetic compositions using them L'OREAL (FR) 1999-07-06 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0826669-B1 Composition for dyeing keratin fibres containing 2-iminoindol derivatives OREAL (FR) 1999-06-30 EP disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed
US-5908932-A Certain pyrroloquinolinones; a new class of GABA brain receptor NEUROGEN CORPORATION (US) 1999-06-01 US disclosed
US-5876465-A Compositions for dyeing keratin fibres containing 2-iminoindoline derivatives and dyeing process L'OREAL (FR) 1999-03-02 US disclosed
EP-0887346-A2 Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists F. HOFFMANN-LA ROCHE AG (CH) 1998-12-30 EP disclosed
US-5744612-A Process for preparation of 5- substituted tetrazoles TOYO KASEI KOGYO COMPANY LIMITED (JP) 1998-04-28 US disclosed
EP-0826669-A1 Composition for dyeing keratin fibres L'OREAL (FR) 1998-03-04 EP disclosed
US-5723460-A Cyclo (alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same CELLTECH THERAPEUTICS LIMITED (GB) 1998-03-03 US disclosed
EP-0796852-A1 Process for preparation of 5-substituted tetrazoles Toyo Kasei Kogyo Company Limited (JP) 1997-09-24 EP disclosed
EP-0640070-B1 STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS CELLTECH THERAPEUTICS LTD (GB) 1997-09-10 EP disclosed
US-5633257-A PHOSPHODIESTERASE INHIBITOR CELLTECH THERAPEUTICS LIMITED (GB) 1997-05-27 US disclosed
US-5622137-A FOR USE IN TESTING COOKED FOODS TRANS WORLD SERVICES (US) 1997-04-22 US disclosed
US-5604235-A DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, BENZODIAZEPINE OVERDOSE; ENHANCEMENT OF MEMORY NEUROGEN CORPORATION (US) 1997-02-18 US disclosed
WO-1996004246-A1 PHENYLACETAMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1996-02-15 WO disclosed
EP-0687697-A2 A carbonate group-modified epoxy resin and thermosetting compositions of resins containing hydroxyalkyl carbonate groups DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1995-12-20 EP disclosed
EP-0669320-A2 Benzoylquinoiline derivatives NIHON BAYER AGROCHEM K.K. (JP) 1995-08-30 EP disclosed
EP-0640070-A1 STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS. CELLTECH THERAPEUTICS LTD (GB) 1995-03-01 EP disclosed
WO-1994026741-A1 CERTAIN PYRROLOQUINOLINONES; A NEW CLASS OF GABE BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1994-11-24 WO disclosed
WO-1994020455-A1 STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1994-09-15 WO disclosed
EP-0307804-B1 Cephem compound and a process for preparation thereof FUJISAWA PHARMACEUTICAL CO (JP) 1993-11-18 EP disclosed
US-5243049-A Gamma-aminobutyric acid antagonist NEUROGEN CORPORATION (US) 1993-09-07 US disclosed
EP-0299379-B1 PENTADIENAMIDE PAF-ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 1993-04-21 EP disclosed
US-5175273-A Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings GENENTECH, INC. (US) 1992-12-29 US disclosed
US-4975438-A ANTICOAGULANT HOFFMANN-LA ROCHE INC. (US) 1990-12-04 US disclosed
US-4956465-A Bactericides BAYER AKTIENGESELLSCHAFT (DE) 1990-09-11 US disclosed
US-4927826-A Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists HOFFMAN-LA ROCHE INC. (US) 1990-05-22 US disclosed
US-4927838-A CARDIOVASCULAR DISORDERS HOFFMAN-LA ROCHE INC. (US) 1990-05-22 US disclosed
US-4916145-A PLATELET ACTIVATING FACTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 1990-04-10 US disclosed
EP-0129509-B1 TRIAZOLO (2,3-C)(1,3)BENZODIAZEPINES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTICAL USE CIBA-GEIGY AG (CH) 1989-08-23 EP disclosed
EP-0310917-A2 Quinolonecarboxylic acids bearing C(7) carbon-functionality and a method for their preparation BAYER AG (DE) 1989-04-12 EP disclosed
EP-0307804-A2 Cephem compound and a process for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-03-22 EP disclosed
EP-0299379-A1 Pentadienamide PAF-antagonists F. HOFFMANN-LA ROCHE AG (CH) 1989-01-18 EP disclosed
US-4788206-A CARDIOVASCULAR DISORDERS, PLATELETS HOFFMANN-LA ROCHE INC. (US) 1988-11-29 US disclosed
US-4786646-A PLATELET ACTIVATING FACTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 1988-11-22 US disclosed
US-4725497-A Unfalsifiable safety paper SOCIETE ANONYME: AUSSEDAT-REY (FR) 1988-02-16 US disclosed
EP-0078709-B1 PREPARATION OF NITROARALKYL CYANIDES AND DERIVATIVES THEREOF ETHYL CORPORATION (US) 1986-10-01 EP disclosed
US-4595535-A Schizophrenia CIBA-GEIGY CORPORATION (US) 1986-06-17 US disclosed
EP-0077662-B1 PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF ETHYL CORPORATION (US) 1985-10-02 EP disclosed
US-4507311-A Imidazo[1,2-c][1,3]benzodiazepines CIBA-GEIGY CORPORATION (US) 1985-03-26 US disclosed
US-4502998-A Nucleophilic substitution process ETHYL CORPORATION (US) 1985-03-05 US disclosed
US-4499026-A Nucleophilic substitution process ETHYL CORPORATION (US) 1985-02-12 US disclosed
EP-0129509-A2 Triazolo (2,3-c)(1,3)benzodiazepines, process for their preparation, pharmaceutical compositions containing them and their therapeutical use CIBA-GEIGY AG (CH) 1984-12-27 EP disclosed
EP-0122109-A2 Preparation of cyano- or aminoalkyl substituted aromatic amines SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-10-17 EP disclosed
US-4476315-A NITROARYLACETIC ACID ESTERS FROM NITROAROMATIC COMPOUNDS ETHYL CORPORATION (US) 1984-10-09 US disclosed
US-4460587-A ANTIPSYCHOTIC AGENTS, ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1984-07-17 US disclosed
US-4460508-A 5-Diazacycloalkylimidazo[1,2-c][1,3]benzodiazepines CIBA-GEIGY CORPORATION (US) 1984-07-17 US disclosed
US-4459232-A NEUROLEPTIC, ANTIHISTAMINES CIBA-GEIGY CORPORATION (US) 1984-07-10 US disclosed
EP-0081461-A2 Imidazobenzodiazepines, process for their preparation, pharmaceutical preparations containing these compounds and their therapeutical use CIBA-GEIGY AG (CH) 1983-06-15 EP disclosed
EP-0078709-A2 Preparation of nitroaralkyl cyanides and derivatives thereof ETHYL CORPORATION (US) 1983-05-11 EP disclosed
EP-0077662-A1 Preparation of nitroarylacetic acid esters and derivatives thereof ETHYL CORPORATION (US) 1983-04-27 EP disclosed
JP-S5562061-A PRODUCTION OF INDOLES IHARA CHEM IND CO LTD 1980-05-10 JP disclosed
JP-S54126726-A HERBICIDE TANABE SEIYAKU CO LTD 1979-10-02 JP disclosed
US-4064136-A FROM A NITRILE, AN ALCOHOL AND ORTHO-SUBSTITUTED AROMATIC AMINE CIBA-GEIGY AG (CH) 1977-12-20 US disclosed
US-4064136-A FROM A NITRILE, AN ALCOHOL AND ORTHO-SUBSTITUTED AROMATIC AMINE CIBA-GEIGY AG (CH) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (40 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306067-A1 Modulators of Chemokine Receptor Activity CCR3, CCR1, CCR4 ALDH1A1 906/4885HPGD 388/4885TSHR 1110/4885
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators GATAD2A, GATAD2B, RUNX1 ALDH1A1 3621/4885HPGD 4556/4885TSHR 3441/4885
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R ALDH1A1 1932/4885HPGD 1814/4885TSHR 1681/4885
US-20050159363-A1 Selective neuronal nitric oxide synthase inhibitors NOS1, NOS3, NOS2 ALDH1A1 1959/4885HPGD 225/4885TSHR 3793/4885
US-20050277630-A1 Antibacterial agents MRPL21, RPN2, FBL ALDH1A1 637/4885HPGD 419/4885TSHR 4486/4885
US-20160166681-A1 TOLL-LIKE RECEPTOR AGONISTS TLR1, TLR7, TLR8 ALDH1A1 1952/4885HPGD 2868/4885TSHR 1137/4885
US-20040215022-A1 Colorant compositions ARSA, TST, IK ALDH1A1 1311/4885HPGD 2922/4885TSHR 1005/4885
US-20160113277-A1 Substituted 5-Hydroxy-2,3-Diphenylpentanonitrile Derivatives, Processes For Their Preparation And Their Use As Herbicides And/Or Plant Growth Regulators HPD, DDT, HDHD5 ALDH1A1 117/4885HPGD 222/4885TSHR 1679/4885
US-20080176830-A1 Compounds, Compositions, and Methods ALPP, PCNA, MKI67 ALDH1A1 2274/4885HPGD 802/4885TSHR 4737/4885
US-10239811-B2 Process for producing reduced coenzyme Q10 NDUFA10, NDUFB10, NDUFA9 ALDH1A1 640/4885HPGD 101/4885TSHR 4853/4885
US-20040256743-A1 Method for producing organic compound by substituting halogen atoms MRPS22, QARS1, MTX2 ALDH1A1 1159/4885HPGD 3905/4885TSHR 3163/4885
US-20140288111-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS ACACA, PC, ACACB ALDH1A1 164/4885HPGD 588/4885TSHR 3693/4885
US-20050239780-A1 Tetrahydropyran derivative APOB, HDLBP, LDLR ALDH1A1 4266/4885HPGD 1530/4885TSHR 2064/4885
US-20100292458-A1 NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS NT5C3B, NSUN2, ERCC4 ALDH1A1 867/4885HPGD 1761/4885TSHR 3311/4885
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB ALDH1A1 164/4885HPGD 588/4885TSHR 3693/4885
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 ALDH1A1 2435/4885HPGD 231/4885TSHR 348/4885
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS ACACA, PC, ACACB ALDH1A1 161/4885HPGD 560/4885TSHR 3681/4885
US-20230110251-A1 NON-AQUEOUS ELECTROLYTE FOR BATTERY, PRECURSOR FOR LITHIUM SECONDARY BATTERY, METHOD FOR MANUFACTURING LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY, PHOSPHAZENE COMPOUND, AND ADDITIVE FOR BATTERY PHOSPHO1, SLC9B2, SLC9A2 ALDH1A1 3982/4885HPGD 2713/4885TSHR 732/4885
US-20040248902-A1 New indole derivatives with 5-HT6 receptor affinity HTR6, HTR5A, HTR7 ALDH1A1 1833/4885HPGD 2230/4885TSHR 182/4885
US-20120276651-A1 FLUORESCENT NANOPROBE FOR DETECTING HYDROGEN PEROXIDE AND FABRICATION METHOD THEREOF GPX4, PPOX, SQOR ALDH1A1 319/4885HPGD 89/4885TSHR 2789/4885
US-20050250796-A1 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease TNF, NOD2, LITAF ALDH1A1 3789/4885HPGD 1359/4885TSHR 1891/4885
US-10021877-B2 Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators HPD, DDT, HDHD5 ALDH1A1 117/4885HPGD 222/4885TSHR 1679/4885
US-20150307440-A1 REDUCED COENZYME Q10 DERIVATIVE AND METHOD FOR PRODUCTION THEREOF NDUFA10, NDUFB10, NDUFAF2 ALDH1A1 719/4885HPGD 244/4885TSHR 3354/4885
US-20180134644-A1 PROCESS FOR PRODUCING REDUCED COENZYME Q10 NDUFA10, NDUFB10, NDUFA9 ALDH1A1 640/4885HPGD 101/4885TSHR 4853/4885
US-20030119751-A1 Selective neuronal nitric oxide synthase inhibitors NOS1, NOS3, NOS2 ALDH1A1 1959/4885HPGD 225/4885TSHR 3793/4885
US-20050171118-A1 New indole derivatives with 5-HT6 receptor affinity HTR6, HTR5A, HTR7 ALDH1A1 2354/4885HPGD 2558/4885TSHR 137/4885
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia PTGDR, GRIN2A, PTGDR2 ALDH1A1 826/4885HPGD 79/4885TSHR 861/4885
US-20040199002-A1 Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor DOHH, NCEH1, NOTUM ALDH1A1 371/4885HPGD 90/4885TSHR 4200/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators GPR119, GIPR, GCGR ALDH1A1 2333/4885HPGD 893/4885TSHR 161/4885
US-10471139-B2 Toll-like receptor agonists TLR1, TLR7, TLR8 ALDH1A1 1952/4885HPGD 2868/4885TSHR 1137/4885
US-20260131016-A1 NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF FCGR2A, FCGR3B, AURKC ALDH1A1 3068/4885HPGD 4647/4885TSHR 142/4885
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB ALDH1A1 164/4885HPGD 588/4885TSHR 3693/4885
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS ACACA, PC, ACACB ALDH1A1 259/4885HPGD 544/4885TSHR 3659/4885
US-20100022601-A1 SULFONAMIDE COMPOUNDS AND THE USE PTH1R, CASR, SOST ALDH1A1 3531/4885HPGD 2157/4885TSHR 17/4885
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity HTR6, HTR5A, HTR7 ALDH1A1 1394/4885HPGD 2411/4885TSHR 176/4885
US-20040215038-A1 Colorant precursor compositions RB1, SULT1A1, CBR1 ALDH1A1 199/4885HPGD 1780/4885TSHR 2621/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP ALDH1A1 608/4885HPGD 271/4885TSHR 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.